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Clinical Case Report and Review
ABSTRACT
Metastasis to the kidney from other primary sites is extremely rare. Previous studies reported the lung as the most 
common primary site. Distant metastasis from the tongue to the kidney is exceedingly rare. Herein, we describe a case 
of metastatic squamous cell carcinoma to the kidney in a 71-year-old male with a detailed discussion of differentiating 
it from potential mimickers. The patient underwent a total glossectomy and bilateral cervical lymph node dissection. 
A diagnosis of well-differentiated squamous cell carcinoma of the tongue was rendered and the tumor was staged 
pT3 pN3b. Within two years of initial presentation, the patient developed widely metastatic disease, including pulmonary 
nodules, renal masses, left adrenal mass, and pancreatic mass. Accurate diagnosis of a secondary involvement of the 
kidney by a metastatic tumor requires the appropriate correlation of clinical and imaging findings as well as morphologic 
and immunohistochemical clues. 
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INTRODUCTION
Squamous cell carcinoma (SCC) is the most 
common oropharyngeal malignancy. It accounts for 
over 90% of all oropharyngeal malignancies. Within 
the oropharynx, 25-40% of these tumors involve 
the tongue.1 5-year survival rate is 50-55%, owing 
primarily to metastatic disease to regional and distant 
sites. The risk of distant metastasis is approximately 
30% for patients with lymph node metastasis, and 
typically occurs 9-12 months after initial diagnosis. The 
most common sites of distant metastatic involvement 
are the lungs and bones.1,2 Metastasis of squamous 
cell carcinoma of the tongue to kidney is exceedingly 
rare, with only two reported cases in the literature.3,4
Herein, we describe a case of metastatic squamous 
cell carcinoma to the kidney in a 71-year-old male.
Differential diagnosis with urothelial carcinoma 
with squamous differentiation and collecting duct 
carcinoma is also discussed. A review of literature 
is also provided in the discussion with an emphasis 
on metastatic tumors to the kidney and metastatic 
squamous cell carcinoma to the kidney in particular.
METHOD
We searched PubMed and Scopus databases 
from their inception (1996 and 2004, respectively) to 
December 2020, using the keywords “metastasis to 
kidney”; “secondary tumors of kidney”; “secondary 
renal neoplasms”; and “metastatic squamous cell 
carcinoma to the kidney”. This was followed by a 
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manual search of the included references. A total of 
18 articles were initially identified. Duplicates were 
removed, and all articles with primary renal neoplasms 
were excluded. Five articles are mainly discussed in the 
review of the literature.
CASE REPORT
A 71-year-old male initially presented with the 
chief complaint of oral cavity mass. Notably, he had 
30 pack-years smoking history. CT neck demonstrated 
right-sided tongue and floor of mouth mass, and 
possible metastatic disease within two right-sided 
cervical lymph nodes. He underwent a PET scan, 
which confirmed a hypermetabolic mass in the oral 
cavity and ipsilateral nodal disease. No sign of distant 
disease was identified at that time. He underwent a 
total glossectomy and bilateral cervical lymph node 
dissection. Pathology revealed an invasive, keratinizing, 
well-differentiated squamous cell carcinoma, with 
and metastatic carcinoma involving bilateral level 
2-4 lymph nodes. A p16 immunohistochemical stain 
was negative. The tumor was staged as pT3 pN3b. 
Subsequently, the patient received adjuvant therapy. 
He presented for his regular follow-up 18 months after 
completion of adjuvant chemotherapy and radiation. 
Surveillance chest computed tomography (CT) scan 
revealed a right upper lobe endobronchial lesion and 
right hilar lymphadenopathy. The biopsy showed 
metastatic SCC in the right upper lobe of the lung. 
Imaging performed five months later showed newly 
developed pulmonary nodules representing additional 
sites of metastatic disease. In addition, abdominal and 
pelvic CT demonstrated newly developed renal masses, 
left adrenal mass, and pancreatic mass, also likely 
representing metastatic disease (Figure 1).
Repeat PET imaging showed interval increase 
in size and number of multiple bilateral pulmonary 
nodules, which demonstrated hypermetabolic activity. 
The left upper lobe nodule measured 1.1 cm, previously 
0.6 cm, with max SUV 4.0. Hypermetabolic bilateral 
hilar, mediastinal, and retrocrural lymphadenopathy 
was also noted. Furthermore, the abdomen/pelvis 
showed hypermetabolic infiltrating masses within the 
superior pole of the right kidney, demonstrating max 
SUV 31.5 and a hypermetabolic left adrenal mass, 
consistent with metastatic disease. In order to confirm 
the radiologic impression, a biopsy of the renal mass 
was performed.
Microscopic examination of the CT-guided biopsy 
of the renal mass revealed infiltrative growth of 
malignant cells with abundant eosinophilic cytoplasm, 
areas of keratinization, and large, vesicular nuclei 
(Figure 2).
Immunohistochemical studies showed the 
tumor cells to be diffusely and strongly positive for 
CK5/6 and negative for PAX8 and CK20 (Figure 3). 
GATA3 was predominantly negative with focal 
weak positivity in some cells. The morphology and 
immunohistochemical profile were interpreted to be 
consistent with metastatic squamous cell carcinoma 
involving the renal parenchyma.
The patient subsequently completed three cycles 
of chemotherapy and immunotherapy. Three months 
Figure 1. CT scan demonstrating ill-defined low-attenuation masses within the superior pole and mid-region of the 
right kidney.
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have elapsed since renal involvement was noted on 
imaging studies, and the patient is alive with widely 
metastatic disease. He is scheduled for a follow-up CT 
for assessment of metastatic disease and treatment 
response.
DISCUSSION
Although metastases from a primary renal tumor 
are fairly common, metastasis to the kidney from 
other primary sites is extremely rare. A comprehensive 
analysis of 151 cases of secondary renal tumors 
revealed that the most common primary sites include 
the lung, gastrointestinal tract, breast, and thyroid.5 
The median patient age was found to be 56.7 years, 
and metastases to the kidney were solitary in 77.5% 
of cases.5 Another series of 43 surgical pathology cases 
found similar results with the median age of 61 years 
and male to female ratio of 1:1.6 The most common 
primary sites in this series included lung, breast, and 
Figure 3. Immunohistochemical staining for anti-CK5/6 (A), anti-GATA3 (B), anti-CK20 (C), anti-PAX8 (D).
Figure 2. Low magnification image showing the tumor infiltrating the renal parenchyma (H&E, 40x); high 
magnification showing cytologic details of the tumor cells (H&E 200x).
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female genital tract.6 Both studies mentioned the 
head and neck region/ear, nose, and throat (ENT) as 
one of the primary sites; however, the specific site 
within the head and neck region or specific tumor 
was not mentioned. Our patient was 71-years-old 
and had two foci of metastatic disease in his right 
kidney. The mainstay of diagnosis is imaging studies. 
Based on imaging findings, renal masses can be 
categorized as benign, primary renal tumor, metastasis, 
and uncertain. In the study by Zhou, C. et al.,5 the 
radiology-pathology concordance was 51%, whereas 
in the study by Wu AJ et al.6 the concordance was 
54%.5,6 In our patient, the radiologic impression was 
that of metastatic disease. Secondary involvement 
of the kidney usually occurs in the setting of widely 
metastatic disease.5,7 Solitary involvement of the kidney 
is less common; however, no other site of metastatic 
disease was identified at the time of renal involvement 
in 37% of patients in the study by Wu AJ et al.6 Solitary 
involvement of the kidney represents an opportunity 
for therapy with curative intent. In the study by Zhou 
C et al.5 surgery with curative intent was performed in 
21 patients.5 Our patient was not a suitable candidate 
for curative surgery owing to widely metastatic disease.
In the study by Wu AJ et al.,6 eight cases (19%) 
were squamous cell carcinomas; however, for all 
eight cases, the primary site was lung.6 In cases of a 
secondary involvement of the kidney by a squamous 
cell carcinoma, it is prudent to rule out other potential 
mimickers such as a urothelial carcinoma with squamous 
differentiation and collecting duct carcinoma. The 
presence of a conventional urothelial carcinoma or an 
in-situ component favors the diagnosis of urothelial 
carcinoma; however, in the absence of these features 
and in the setting of extensive squamous differentiation, 
the distinction is extremely challenging in a core biopsy 
as well as a resection specimen. Immunohistochemistry 
is potentially useful but not entirely diagnostic because 
of overlapping features. Squamous cell carcinomas 
are usually CK20 negative, whereas a subset of 
urothelial carcinomas with squamous differentiation 
are positive. CK7 usually shows positivity in urothelial 
tumors and is predominantly negative in squamous cell 
carcinoma. Strong and diffuse GATA3 positivity favors 
a urothelial primary; however, a weak and patchy 
GATA3 expression has been reported in squamous 
cell carcinomas.8-10 The distinction from collecting duct 
carcinoma can be challenging on morphologic grounds 
alone. Immunohistochemical stains, including PAX-8 
and CK5/6, can be helpful in this distinction. Our case 
was strongly positive for CK5/6 and negative for PAX8, 
and CK20. GATA3 was negative with focal weak, non-
specific positivity in our case. Accurate diagnosis requires 
the correlation of all the relevant information, including 
the clinical history, radiologic findings, and morphologic 
and immunohistochemical features. Known history of a 
primary tumor is an extremely helpful clue. In the study 
by Wu AJ et al.,6 88% of patients had a known history 
of primary disease, and in an additional 9%, the primary 
tumor and metastasis were diagnosed concurrently.6 
The time interval between the initial diagnosis and 
the secondary involvement of the kidney is variable. 
Wu AJ et al.6 reported the median time interval to be 
3.1 years (range 0 to 21.6 years).6 The time interval was 
greater than 10 years in 19% of their patients.6 In the 
case reported by Singh GK et al.,3 the time interval was 
18 months, while in the case reported by Thyavihally 
Y et al.,4 the time interval was 4 months.3,4 Our patient 
developed lung metastasis 18 months after completion 
of therapy for the primary tumor and 5 months later 
developed widely metastatic disease, including the 
kidney involvement.
In patients with oropharyngeal squamous cell 
carcinoma, the risk of distant metastasis is approximately 
30% for patients with lymph node metastasis.2 The 
5-year relative survival for distant metastatic oral 
cavity and pharynx cancer is 40.1%.11 In the study by 
Zhou C et al.,5 the median overall survival (OS) from 
the time of renal metastasis diagnosis was 1.13 years.5 
The OS from the time of renal metastasis diagnosis was 
2.24 years for patients who underwent renal surgery 
compared to 0.72 years or patients who did not undergo 
renal surgery (log-rank P < 0.001).5 Our patient was 
alive with the widely metastatic disease three months 
after renal involvement was noted on imaging studies.
CONCLUSION
Secondary involvement of the kidney by primary 
tumors of different organs is rare. Appropriate 
clinicopathologic correlation is immensely helpful in 
making the correct diagnosis. Median OS from the 
time of renal metastasis is just over a year, and surgical 
intervention may be helpful in improving the OS to 
over 2 years.
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